Statement from Sandra C. Raymond, President and CEO of the Lupus Foundation of America
Foundation-funded research studies highlighted at premier rheumatology meeting in Boston.
Award is the largest amount allocated to lupus since 2006
Lupus Foundation of America supported study demonstrates that blocking STAT5 reduces the production of CD154 by half.
Adolescent-onset lupus has worse prognosis and increased risk of lupus-related kidney disease and death.
Sandra C. Raymond, President & CEO of the Lupus Foundation of America, issued the following statement in response to Eli Lilly and Company’s announcement of the results of two Phase III clinical trials of tabalumab.
Whether it is Grandma’s sweet potato casserole or the family’s favorite gravy, holidays aren’t just filled with memories, but sugar, sodium, and fat, too. But with a few adjustments, it’s easy to lighten up the feast without losing the dishes you love.
The Lupus Foundation of America announced four grants that will allow lupus investigators to continue critical lupus research. Another grant will be used to develop a groundbreaking diagnostic tool for children with lupus-related kidney inflammation, or lupus nephritis.